Clinical trials: Locally Advanced Head and Neck Carcinoma
Esophageal Cancer
S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00109850
- Testing
- cetuximab, cisplatin, irinotecan hydrochloride
- Where
- 132 sites in United States
- Volunteers
- 22 people
- Sponsor
- SWOG Cancer Research Network
Carcinoma of the Head and Neck
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
This study is conducted in Japanese newly diagnosed locally advanced SCCHN patients in order to assess tolerability and feasibility of Cetuximab plus concomitant boost radiotherapy (RT) regimen (the study treatment) and its…
- Trial name
- NCT00865098
- Testing
- Cetuximab
- Where
- 4 sites in Japan
- Volunteers
- 27 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Thyroid Cancer, Anaplastic Thyroid Cancer
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid
- Conditions
- Thyroid Cancer, Anaplastic Thyroid Cancer, Undifferentiated Thyroid Cancer
- Trial name
- NCT04552769
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Esophageal Squamous Cell Carcinoma
Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable…
- Trial name
- AdvanTIG-203 (NCT04732494)
- Testing
- Tislelizumab, Ociperlimab
- Where
- 86 sites in China, France and 4 more
- Volunteers
- 125 people
- Sponsor
- BeiGene
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma
A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
This phase I/II trial studies how well PDS0101 alone or in combination with pembrolizumab works to shrink tumor in patients with human papillomavirus-associated oropharynx cancer that has spread to nearby tissue or lymph nodes…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus-Related Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
- Trial name
- NCT05232851
- Testing
- Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101, Pembrolizumab, Computed Tomography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland.
- Conditions
- Thyroid Neoplasms, Poorly Differentiated and Undifferentiated Thyroid Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03002623
- Testing
- CUDC-907
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Head and Neck
Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC
Head and neck cancer squamous cell carcinoma (HNSCC) is a disease with poor survival, especially for African Americans, despite intense treatment including surgery, radiation, and chemotherapy.
- Trial name
- NCT04098458
- Testing
- NDURE
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site
This phase II trial tests whether atezolizumab works to shrink tumors before surgery in patients with head and neck squamous cell cancer with an unknown or historic primary site that has spread to other places in the lymph nodes…
- Conditions
- Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT05110781
- Testing
- Atezolizumab, Radiation Therapy, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Davis
Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)
In this trial, the objectives are to determine the efficacy and toxicity of induction chemotherapy (IC) with nab-paclitaxel + cisplatin (Arm 1: AP) and with nab-paclitaxel (Arm 2: A) alone in patients with HNSCC, and to compare…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck, Cancer of the Head and Neck
- Trial name
- APA (NCT02573493)
- Testing
- nab-Paclitaxel, Cisplatin, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine
Cancer of Head and Neck
Single-arm Phase II Study of NDURE for Patients With HNC
This study will evaluate whether a new patient navigation intervention can decrease delays starting post-operative radiation therapy after surgery for white and African-American head and neck cancer patients.
- Trial name
- NDURE (NCT03821064)
- Testing
- Patient Navigation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Medical University of South Carolina
Cancer of Head and Neck
Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Head and Neck Cancer
The purpose of this study is to determine if Transcranial Direct Current Stimulation (tDCS) can reduce pain perception associated with the effects of receiving definitive radiation therapy or chemoradiotherapy in head and neck…
- Trial name
- NCT02366611
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Michigan
Head and Neck Cancer
Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC)
This is a single-arm, phase II trial to characterize the clinical outcome of standard of care, cetuximab concurrent with radiation, in a special population (head and neck cancer patients who cannot tolerate concurrent…
- Trial name
- NCT00904345
- Testing
- Cetuximab, 50-60 Gy and 70 Gy
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan Rogel Cancer Center
Head and Neck Cancer
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00352105
- Testing
- cisplatin, fluorouracil, Iressa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- David Adelstein
Head and Neck Cancer
A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC
Primary Objective for Phase I 1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination with cetuximab/RT in Cohort A. 2.
- Trial name
- Dasatinib (NCT00882583)
- Testing
- Cetuximab, Dasatinib, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Cancer
Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
The standard treatment of surgery followed by radiation therapy can stop tumors from growing in the head and neck region in most patients. However, the cancer can recur or can spread to other parts of the body.
- Trial name
- NCT01979211
- Testing
- Cetuximab, Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Cincinnati
Human Papilloma Virus, Squamous Cell Carcinoma
De-Escalation Therapy for Human Papillomavirus Negative Disease
This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the…
- Conditions
- Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma
- Trial name
- DEPEND (NCT03944915)
- Testing
- Carboplatin, Paclitaxel, Nivolumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Head and Neck Cancer
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA)
The purpose of this study is to determine the safety and effectiveness of treatment with Tarceva (Erlotinib) and RADPLAT (RADiation and intraarterial cisPLATin) for patients with Head and Neck cancer
- Trial name
- NCT00304278
- Testing
- Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), Radiation Therapy (RAD)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Southern Illinois University
Cancer of Head, Cancer of Head and Neck
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
The objectives for this study is as follows: Primary: To evaluate the progression-free survival of locoregionally advanced (stages III/IV) SCCHN patients undergoing postoperative chemoradiotherapy with panitumumab.
- Conditions
- Cancer of Head, Cancer of Head and Neck, Cancer of Neck, Cancer of the Head
- Trial name
- NCT00798655
- Testing
- Panitumumab, Cisplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Robert Ferris
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Head and Neck Cancer
Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00720304
- Testing
- docetaxel, erlotinib hydrochloride, fluorescence in situ hybridization
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Case Comprehensive Cancer Center